Notice

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at USA.gov.

Networks

NIAID participates in or funds many different consortia, clinical trial programs, networks, and research collaborations that help to move science forward. These are listed here, with new ones added all the time. Use the Search by Keyword field to narrow your search.

Showing results filtered by:

This program aims to advance novel vaccine adjuvants toward licensure for human use. The program supports the optimization of adjuvant candidates; vaccine formulation and preclinical adjuvant pharmacology, toxicity, and efficacy studies.

In 2014, NIAID established the Centers of Excellence for Translational Research (CETR) program. Supported translational activities will range from very early discovery-based efforts to late-stage preclinical development.

The long-term goal of the Cooperative Centers on Human Immunology (CCHI) program is the translation of immunology research into clinical applications in humans in the area of infectious disease.

European and Developing Countries Clinical Trials Partnership (EDCTP)  funds research for prevention and treatment of HIV/AIDS, tuberculosis, malaria, and neglected infectious diseases in sub-Saharan Africa.

 

The HIV Vaccine Trials Network (HVTN) is the world’s largest publicly-funded international collaboration focused on the development of vaccines to prevent HIV/AIDS.

This program supports the discovery and analysis of combination adjuvants. Combining different adjuvants can improve the immune response that a vaccine induces and the protection it provides. However, little is known about how to best combine different adjuvants to optimize vaccine efficacy.

The Systems Approach to Immunity and Inflammation Program conducts forward genetic screens of mutant or genetically diverse mice, combined with systems level analysis, to identify previously unappreciated key immune regulatory genes, signaling pathways, or mechanisms; and includes validation of these pathways in human cells and tissues.

The U.S. Military HIV Research Program (MHRP) was established in 1985 to protect U.S. troops entering endemic HIV areas and is dedicated to HIV vaccine development, prevention, disease surveillance, and HIV care and treatment. NIAID plans and executes HIV/AIDS research projects annually with MHRP through an interagency agreement on HIV vaccine research.

The Vaccine and Treatment Evaluation Units (VTEUs) have played a key role in NIAID’s effort to develop new and improved vaccines and therapies against infectious diseases for over four decades. They have conducted hundreds of clinical trials, many of which have contributed to vaccine licensure.